RedHill Biopharma Ltd.

RedHill Biopharma veröffentlicht Highlights aus Q1/2022: Im Plan zu einem positiven operativen Cashflow in H2/22

RedHill gibt effektive Hemmung der Omikron-Variante durch seinen oralen COVID-19-Wirkstoffkandidaten Opaganib in vitro bekannt

RedHill gibt effektive in vitro-Hemmung der Omikron-Variante durch seinen oralen COVID-19-Wirkstoffkandidat Opaganib in vivo bekannt

​​​​​​​RedHill und Kukbo unterzeichnen Lizenzvereinbarung für oral verabreichtes Opaganib zur Behandlung von COVID-19 in Südkorea

RedHill gibt positive Phase-2-Studienergebnisse mit oral verabreichtem RHB-107 an nicht hospitalisierten COVID-19-Patienten bekannt

RedHill Biopharma meldet Rekord-Quartalsumsatz und erreicht zum ersten Mal kommerzielle Gewinnzone

RedHill Biopharmas orales Opaganib senkt in Kombination mit Remdesivir und Kortikosteroiden die Sterblichkeitsrate bei schwerer COVID-19 um 70 %

Oral verabreichtes Opaganib von RedHill Biopharma zeigt signifikante Verbesserung der Viruselimination in Phase-2/3-Studie bei schwer erkrankten, hospitalisierten COVID-19-Patienten

RedHill Biopharma Reports 2017 Third Quarter Financial Results

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT(R) for Migraines

RedHill Biopharma to Present at the BIO-Europe 2017 Conference

RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA(R) in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018

RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat Cancers

RedHill Biopharma Ltd.: RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules :

RedHill Biopharma Provides 2017 Semi-Annual Business Update

RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn’s Disease

RedHill Biopharma Reports 2017 Second Quarter Financial Results

RedHill Biopharma Announces Last Patient Visit in BEKINDA(R) Phase II Study for IBS-D

RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Updated on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease

RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection

RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA(R) for Acute Gastroenteritis

RedHill Biopharma Initiates Promotion of Donnatal(R) and EnteraGam(R) in the U.S.

RedHill Biopharma Reports 2017 First Quarter Financial Results

RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA(R) Phase II Study for IBS-D

RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA(R)

RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam(R)